HiFiBiO’s platform for antibody screening applied to COVID-19; plus Fundamental’s peptide mimetics for stroke, and BMS-IONpath

HiFiBiO’s antibody discovery platform
HiFiBiO Therapeutics has described in a Nature Biotechnology article its CelliGO microfluidics platform for high-throughput screening of antibodies secreted from single B cells. The company is using the platform to screen blood samples from recovered COVID-19 patients to develop neutralizing antibodies against SARS-CoV-2. The platform uses fluorescence-based functional assays and DNA sequencing of immunoglobulin variable domains to select therapeutic antibody candidates within 3.5 days. In mice immunized with various antigens including tetanus toxoid, up to 93% of CelliGO-identified antibodies bound the target antigens in vitro.

VEGF-D peptide mimetics for stroke...